Court invalidates patents claimed against CareDx

BRISBANE, Calif. - CareDx, Inc. (NASDAQ: NASDAQ:CDNA), a company specializing in healthcare solutions for transplant patients, announced the District Court’s decision to invalidate the patent claims brought against it by a competitor. The court ruled that the patents in question did not meet the required detail to describe the claimed invention adequately. With a market capitalization of $1.15 billion and a strong current ratio of 4.1, InvestingPro data shows CareDx maintains solid financial footing, holding more cash than debt on its balance sheet.

The litigation centered on CareDx’s AlloSure®, the first donor-derived cell-free DNA assay for detecting organ rejection in transplant patients. AlloSure® was introduced in 2017 for kidney transplant patients and later for heart and lung transplants.

The ruling overturns a previous jury verdict in favor of the plaintiff, Natera (NASDAQ:NTRA). CareDx has expressed confidence in the decision, viewing it as a positive outcome for transplant patients relying on its technology.

Furthermore, the patent underlying the $96 million verdict against CareDx is also undergoing a reexamination by the United States Patent and Trademark Office (PTO). On February 14, 2025, the PTO issued a non-final Office action rejecting the claims that CareDx was found to have infringed upon.

CareDx remains prepared to defend its technology should Natera choose to appeal the court’s decision. The company continues its focus on providing genomics-based information and healthcare solutions to support the transplant community.

The recent court ruling and PTO’s non-final Office action are part of ongoing legal proceedings, and CareDx has cautioned that the outcomes are subject to risks and uncertainties that could affect the company’s future results.

This report is based on a press release statement from CareDx, Inc.

In other recent news, CareDx, Inc. has announced preliminary financial results for the fourth quarter and full year ending December 31, 2024, indicating a projected revenue increase of approximately 30% year-over-year, with earnings expected to be between $85 million and $86 million. Despite this growth, the company anticipates a GAAP loss of about $32 million to $34 million for the fourth quarter, although adjusted EBITDA is expected to reflect a gain between $8 million and $9 million. In another development, CareDx has expanded into hematology oncology by partnering with TC BioPharm for the ACHIEVE clinical trial, utilizing its AlloCell solution to monitor cell therapy patients. Additionally, the company has revised its compensation policy for non-employee directors, adjusting stock award vesting schedules and removing extra quarterly retainers for the Board Chairperson. CareDx also published a study in Transplant International showing that its AlloSeq cfDNA test matches the performance of its established AlloSure Kidney test in detecting kidney allograft rejection. These developments reflect CareDx’s ongoing efforts in financial growth, strategic expansion, and corporate governance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.